Teva Pharmaceutical Indus 주식 (NYSE: TEVA)

에 대한 최신 뉴스 Teva Pharmaceutical Indus (NYSE:TEVA) 주식

Teva Pharmaceutical Indus

Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.

Analysts expect Ford Motor Co. (NYSE: F) to post quarterly earnings at 33 cents per share on revenue of $43.25 billion after the closing bell. Ford shares fell 0.7% to $10.09 in after-hours trading.

Equities

News

Markets

Tech

General

ADBE

ADSK

AMZN

AVGO

GOOGL

MSFT

NTRA

NVDA

SBUX

TEVA

TSLA

최근 13F 공시에 따르면 억만장자 투자자 스탠리 드러켄밀러의 가족 투자사인 듀케인(Duquesne)은 브로드컴(NASDAQ:AVGO) 주식을 전량 매각하는 동시에 주요 기술 기업에 대한 투자를 늘렸다.

스탠리 드러켄밀러의 4분기 포트폴리오: 브로드컴 처분, 테슬라·아마존 등 대형 기술주에 대규모 투자

Uber Weride

Mid Cap

Movers

Trading Ideas

AXSM

CRSP

MKGAF

MKKGY

RXRX

SWTX

VNET

이들 10개 대형주는 지난 주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 위라이드(NASDAQ:WRD)의 주식이 97.62% 급등했다. 이는 엔비디아(NASDAQ:NVDA)가 13F 제출을 통해 174만 주의 지분을 보유하고 있다고 공개한 후 발생한 일이다.

위라이드, 크리스퍼 및 진DX 등 지난주 최대 상승한 10개의 중형주 (2월 10일-2월 14일)

Record-Breaking Market Losses: Nvidia Tops The List Of The 10 Largest Wipeouts In History

Large Cap

DECK

MANH

SMCI

이들 12개 대형주들은 지난 주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 맨해튼 어소시에이츠(NASDAQ:MANH)의 주식은 회사가 2025 회계연도에 대한 부진한 가이던스를 발표한 후 27.92% 급락했다. 애널리스트들이 가격 예측을 하향 조정한 것도 영향을 미쳤다.

엔비디아, 테바 파마 및 UPS 등 지난주 하락한 12개의 대형주 (1월 27일-1월 31일)

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Industries Ltd

TEVA PHARM INDUS LTD ORD by Teva Pharmaceutical Industries Ltd.

TEVANO SYS HLDGS INC by Tevano Systems Holdings Inc.

Tevano Systems Holdings Inc

Goldman Sachs has initiated coverage of generic pharmaceutical stocks, highlighting the sector's strong long-term <a href="https://www.benzinga.com/general/health-care">potential despite recent volatility</a>. 
Analyst Matt Dellatorre points to a mix of company-specific challenges—such as fiscal 2025 guidance—and broader industry concerns like tariffs and drug pricing. 
Still, he argues that many of these stocks are attractively valued and represent businesses well-positioned for growth.
See Also: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45819356/dogecoin-down-10-on-the-week-is-the-musk-trump-spat-bearish-for-doge">Dogecoin Down 10% On The Week: Is The Musk-Trump Spat Bearish For DOGE?</a>
<h2 class="wp-block-heading">Teva Pharmaceutical </h2>
Goldman Sachs has initiated Teva Pharmaceutical Industries Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) with a Buy rating, with a <a href="https://www.benzinga.com/quote/TEVA/analyst-ratings" target="_blank" rel="noreferrer noopener">price target of $24</a>. 
Dellatorre sees an improvement in the core business, with an upside to consensus EBITDA estimates driven by strong growth in the branded segment.
On the generics side, Goldman Sachs expects limited growth over the next few years as an expanding biosimilar portfolio. Other new product launches are offset by the Revlimid settlement expiration in 2026.
The analyst expects robust growth on continued momentum for key assets on the branded side, acknowledging the industry-wide Part D re-design hit to <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45260240/teva-shares-climb-on-profit-beat-700-million-cost-plan-biopharma-pivot-momentum" rel="noreferrer noopener">2025 growth and margins</a>.
Goldman views Teva&#8217;s biosimilar portfolio as an important long-term growth driver for the generics business. The company now has 10 in-line assets and 13 biosimilars in the pipeline. 2027 expects five potential launches in the U.S. and three in the EU/exUS.
Teva expects biosimilar revenue of around $400 million in fiscal 2024 to double by fiscal 2027.
Goldman writes that Teva&#8217;s branded pipeline represents a significant valuation lever. It sees a favorable catalyst path over the next 24 months. The analyst sees an attractive catalyst path, with multiple opportunities to re-rate as these pipeline assets are de-risked.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/05/45297381/viatris-shares-positive-data-from-investigational-contraceptive-patch-fast-acting-meloxicam-reduces-opioid-use-in-surgery-pain-trials" rel="noreferrer noopener">Viatris Discloses Positive Data From 2 Drugs In Earnings Report, Stock Soars</a>
<h2 class="wp-block-heading">Viatris</h2>
Dellatorre initiated Viatris Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>) with a Neutral rating and <a href="https://www.benzinga.com/quote/VTRS/analyst-ratings" target="_blank" rel="noreferrer noopener">price target of $10</a>. Why? There&#8217;s a lack of clarity on the growth outlook for the core business given current structural dynamics in the generics and branded segments.
More specifically, on the generics side, <a target="_blank" href="https://www.benzinga.com/25/05/45297381/viatris-shares-positive-data-from-investigational-contraceptive-patch-fast-acting-meloxicam-reduces-opioid-use-in-surgery-pain-trials" rel="noreferrer noopener">excluding Indore</a>, Goldman is optimistic about recent underlying trends and continues to monitor Viatris&#8217; ability to meaningfully offset price erosion via new product launches and progress on the ongoing portfolio optimization.
In the branded drugs segment, the analyst writes that older products losing market share in the U.S. and Asia have hurt growth, and it is watching for signs of recovery. However, there have been signs of stabilization in developed markets, China, and other emerging markets in recent quarters. Despite the decline, these products still generate steady cash, and Goldman is observing how the company reinvests this into new growth opportunities.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/05/45175642/drug-maker-amneal-highlights-strong-commercial-uptake-for-parkinsons-drug-but-q1-earnings-are-mixed" rel="noreferrer noopener">Drug Maker Amneal Highlights Strong Commercial Uptake For Parkinson&#8217;s Drug But Q1 Earnings Are Mixed</a>
<h2 class="wp-block-heading">Amneal Pharmaceuticals&nbsp;</h2>
Goldman initiated Amneal (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRX#NASDAQ">AMRX</a>) with a Buy rating and a <a href="https://www.benzinga.com/quote/AMRX/analyst-ratings" target="_blank" rel="noreferrer noopener">price target of $12</a>.
The analyst is optimistic about the growth outlook for Amneal&#8217;s core business. He cites a strong product pipeline and track record of execution through various market environments.
Goldman has confidence in Amneal&#8217;s ability to continue to offset typical price erosion via new product launches. Amneal also has structural tailwinds as the company aggressively shifts its focus toward higher-value products.
In the branded segment, analyst Dellatorre is positive on the ongoing launch of the next-generation <a target="_blank" href="https://www.benzinga.com/25/04/44673049/amneals-combination-drug-shows-improved-sleep-quality-in-parkinsons-disease-patients" rel="noreferrer noopener">Parkinson&#8217;s disease drug</a> Crexont to ultimately offset Rytary&#8217;s 2025 loss of exclusivity and the endocrinology franchise&#8217;s stable growth outlook.
Price Action: TEVA stock is up 1.39% at $17.49, AMRX stock is up 2.37% at $7.34, and VTRS stock is up 2.07% at $8.64 at the last check on Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/06/45800081/dr-reddys-and-alvotech-join-hands-to-develop-biosimilar-for-mercks-blockbuster-cancer-drug" target="_blank" rel="noreferrer noopener">Dr Reddy&#8217;s And Alvotech Join Hands To Develop Biosimilar For Merck&#8217;s Blockbuster Cancer Drug</a></li>
</ul>
Image: Shutterstock

Analyst Color

Biotech

Health Care

Price Target

Initiation

Analyst Ratings

AMRX

VTRS

Goldman Sachs Bullish On Branded Drug Upside At Teva: What About Viatris?

Goldman Sachs analyst Matt Dellatorre initiates coverage on Teva Pharmaceutical Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) with a Buy rating and announces Price Target of $24.

Goldman Sachs Initiates Coverage On Teva Pharmaceutical Indus with Buy Rating, Announces Price Target of $24

Teva Pharmaceutical Indus's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) short percent of float has risen 36.14% since its last report. The company recently reported that it has 38.70 million shares sold short, which is 3.39% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.36 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Teva Pharmaceutical Indus Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749128429_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Teva Pharmaceutical Indus has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Teva Pharmaceutical Indus's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Teva Pharmaceutical Indus's peer group average for short interest as a percentage of float is 3.58%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Do Investors Really Feel About Teva Pharmaceutical Indus?

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NTRA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$175.00</td>
<td>$36.9K</td>
<td>10</td>
<td>1.3K</td>
</tr>
<tr>
<td>TEVA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$18.00</td>
<td>$25.4K</td>
<td>49.9K</td>
<td>898</td>
</tr>
<tr>
<td>SRDX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$30.00</td>
<td>$190.0K</td>
<td>502</td>
<td>500</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$310.00</td>
<td>$43.5K</td>
<td>3.0K</td>
<td>494</td>
</tr>
<tr>
<td>AKBA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$2.50</td>
<td>$31.0K</td>
<td>438</td>
<td>350</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$70.00</td>
<td>$88.3K</td>
<td>576</td>
<td>217</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$710.00</td>
<td>$63.4K</td>
<td>25</td>
<td>13</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$115.00</td>
<td>$87.5K</td>
<td>12</td>
<td>10</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>09/18/26</td>
<td>$120.00</td>
<td>$35.6K</td>
<td>0</td>
<td>5</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• For NTRA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>), we notice a call option trade that happens to be bullish, expiring in 107 day(s) on September 19, 2025. This event was a transfer of 26 contract(s) at a $175.00 strike. The total cost received by the writing party (or parties) was $36.9K, with a price of $1420.0 per contract. There were 10 open contracts at this strike prior to today, and today 1350 contract(s) were bought and sold. 
• For TEVA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>), we notice a call option sweep that happens to be bullish, expiring in 16 day(s) on June 20, 2025. This event was a transfer of 750 contract(s) at a $18.00 strike. This particular call needed to be split into 8 different trades to become filled. The total cost received by the writing party (or parties) was $25.4K, with a price of $34.0 per contract. There were 49987 open contracts at this strike prior to today, and today 898 contract(s) were bought and sold. 
• Regarding SRDX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRDX#NASDAQ">SRDX</a>), we observe a call option trade with bullish sentiment. It expires in 72 day(s) on August 15, 2025. Parties traded 500 contract(s) at a $30.00 strike. The total cost received by the writing party (or parties) was $190.0K, with a price of $380.0 per contract. There were 502 open contracts at this strike prior to today, and today 500 contract(s) were bought and sold. 
• Regarding UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we observe a call option sweep with bullish sentiment. It expires in 44 day(s) on July 18, 2025. Parties traded 38 contract(s) at a $310.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $43.5K, with a price of $1145.0 per contract. There were 3038 open contracts at this strike prior to today, and today 494 contract(s) were bought and sold. 
• Regarding AKBA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>), we observe a call option trade with bullish sentiment. It expires in 226 day(s) on January 16, 2026. Parties traded 200 contract(s) at a $2.50 strike. The total cost received by the writing party (or parties) was $31.0K, with a price of $155.0 per contract. There were 438 open contracts at this strike prior to today, and today 350 contract(s) were bought and sold. 
• Regarding MRK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), we observe a call option trade with bearish sentiment. It expires in 16 day(s) on June 20, 2025. Parties traded 100 contract(s) at a $70.00 strike. The total cost received by the writing party (or parties) was $88.3K, with a price of $883.0 per contract. There were 576 open contracts at this strike prior to today, and today 217 contract(s) were bought and sold. 
• For LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we notice a call option trade that happens to be bullish, expiring in 198 day(s) on December 19, 2025. This event was a transfer of 5 contract(s) at a $710.00 strike. The total cost received by the writing party (or parties) was $63.4K, with a price of $12690.0 per contract. There were 25 open contracts at this strike prior to today, and today 13 contract(s) were bought and sold. 
• For MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we notice a put option sweep that happens to be neutral, expiring in 226 day(s) on January 16, 2026. This event was a transfer of 10 contract(s) at a $115.00 strike. This particular put needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $87.5K, with a price of $8753.0 per contract. There were 12 open contracts at this strike prior to today, and today 10 contract(s) were bought and sold. 
• For ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we notice a call option trade that happens to be neutral, expiring in 471 day(s) on September 18, 2026. This event was a transfer of 5 contract(s) at a $120.00 strike. The total cost received by the writing party (or parties) was $35.6K, with a price of $7130.0 per contract. There were 0 open contracts at this strike prior to today, and today 5 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

ABBV

AKBA

MRNA

SRDX

9 Health Care Stocks Whale Activity In Today's Session

<ul>
<li>Real-world claims studies evaluating UZEDY&#xAE; (risperidone) also show improved adherence and persistence rates, fewer inpatient, outpatient and emergency department (ED) visits versus second-generation daily oral options</li>
<li>Latest Phase 3 SOLARIS data show no suspected or confirmed PDSS events with TEV-'749 after more than 3,400 subcutaneous injections in study participants to date</li>
<li>As a leader in neuroscience, Teva is committed to researching and developing long-acting treatment options that help address unmet needs for individuals living with schizophrenia</li>
</ul>

Reported Friday, Teva Showcases Real-World UZEDY Data Demonstrating Lower Relapse Rates, Better Adherence, And Reduced Healthcare Use Compared To Oral Antipsychotics

Israeli multinational pharmaceutical company Teva Pharmaceutical Industries Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) hosted 2025 Innovation &amp; Strategy Day on Thursday to launch the acceleration phase of its &#8220;Pivot to Growth&#8221; strategy and to discuss portfolio priorities.
The company outlined its plan to evolve into a leading biopharmaceutical company, emphasizing its innovative medicines franchise and a strong generics and biosimilars portfolio.
President and CEO Richard Francis said the company is entering a new chapter focused on scaling its innovative medicines franchise while maintaining strength in generics and biosimilars.
Francis highlighted that Teva has completed Phase 1 of its "Pivot to Growth" plan, achieving nine consecutive <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45666576/teva-reaffirms-pivot-to-growth-strategy-progress-with-launch-of-acceleration-phase-at-2025-innovat" rel="noreferrer noopener">quarters of growth</a>.
Also Read: <a href="https://www.benzinga.com/general/biotech/25/05/45260240/teva-shares-climb-on-profit-beat-700-million-cost-plan-biopharma-pivot-momentum" target="_blank" rel="noreferrer noopener">Teva Shares Climb On Profit Beat, $700 Million Cost Plan, Biopharma Pivot Momentum</a>
The company's innovative medicines portfolio, including Austedo, Ajovy, and Uzedy, generated over $2.3 billion in 2024 revenue.
Teva's generics business has also rebounded, with a 5% increase in revenue across regions and a top-three global portfolio that may yield five new product launches by 2027.
&#8220;The past two years have been about returning to growth&#8230;Now, we are accelerating our growth into a leading biopharma company with a strong innovative medicines franchise and a powerhouse generics and biosimilars portfolio,&#8221; Francis said.
Teva aims to build a $5 billion innovative medicines franchise by 2030, led by its key assets and a strong late-stage pipeline.
Austedo is expected to surpass $2.5 billion in sales by 2027 and reach over $3 billion by 2030. Ajovy is in 43 countries, with additional launches expected this year. Uzedy has rapidly captured over 60% of the risperidone long-acting injectable (LAI) market, and the upcoming olanzapine LAI is expected to expand Teva's footprint in schizophrenia treatment.
The late-stage pipeline includes promising assets such as duvakitug for inflammatory bowel disease, DARI for asthma, and emrusolmin for Multiple System Atrophy, each carrying multibillion-dollar peak sales potential.
TEV-‘408, an anti-IL-15 antibody for celiac disease, has received FDA fast-track status and could exceed $1 billion in peak sales.
Teva's generics, biosimilars, and over-the-counter (OTC) segments remain critical revenue drivers.
The company has 13 biosimilars in development, with five launches planned by 2027. Its $1.1 billion OTC business continues to outperform the market with double-digit growth, while ongoing manufacturing transformations aim to improve competitiveness and margins.
Teva reaffirmed its 2027 financial targets, including a 30% operating margin, more than $2.7 billion in free cash flow, and over $700 million in savings from operational efficiencies.
Price Action: TEVA stock is trading lower by 3.55% to $17.55 at last check Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45670275/build-a-bear-sticks-to-outlook-despite-tariff-pressure-stock-soars-25" target="_blank" rel="noreferrer noopener">Build-A-Bear Sticks To Outlook Despite Tariff Pressure, Stock Soars 25%</a></li>
</ul>
Photo via Shutterstock

Teva Reaffirms Growth Strategy, Eyes $5 Billion Innovative Franchise By 2030

Teva Provides Updates Ahead Of Its Innovation and Strategy Day; Say sInnovative Medicines Franchise On Track To Exceed $5B By 2030, Reaffirms 2027 Financial Targets

In the last three months, 4 analysts have published ratings on Teva Pharmaceutical Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>), offering a diverse range of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Teva Pharmaceutical Indus and provided 12-month price targets. The average target is $22.5, accompanied by a high estimate of $25.00 and a low estimate of $20.00. Witnessing a positive shift, the current average has risen by 5.49% from the previous average price target of $21.33.
<img src="https://www.benzinga.com/files/images/story/2025/1748466040_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The analysis of recent analyst actions sheds light on the perception of Teva Pharmaceutical Indus by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Les Sulewski</td>
<td>Truist Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$25.00</td>
<td>-</td>
</tr>
<tr>
<td>Chris Schott</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$23.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Jason Gerberry</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$22.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Jason Gerberry</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$20.00</td>
<td>$23.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Teva Pharmaceutical Indus. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Teva Pharmaceutical Indus compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Teva Pharmaceutical Indus's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/TEVA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Teva Pharmaceutical Indus analyst ratings.</a>
<h2>Unveiling the Story Behind Teva Pharmaceutical Indus</h2>
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
<h3>Understanding the Numbers: Teva Pharmaceutical Indus's Finances</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Teva Pharmaceutical Indus's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 1.89% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Teva Pharmaceutical Indus's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 5.5%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Teva Pharmaceutical Indus's ROE excels beyond industry benchmarks, reaching 3.68%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Teva Pharmaceutical Indus's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.55%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 2.71, caution is advised due to increased financial risk.
<h2>The Significance of Analyst Ratings Explained</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Teva Pharmaceutical Indus Stands With Analysts

Truist Securities analyst Les Sulewski initiates coverage on Teva Pharmaceutical Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) with a Buy rating and announces Price Target of $25.

Truist Securities Initiates Coverage On Teva Pharmaceutical Indus with Buy Rating, Announces Price Target of $25

Teva Pharmaceutical Industries Announces That FDA Granted Fast Track Designation For Investigational TEV-53408, An Anti-IL-15 Antibody, For The Treatment Of People With Celiac Disease On A Gluten-Free Diet; TEV-53408 Is Currently Being Evaluated In A Phase 2a Trial To Assess The Efficacy And Safety In Adults With Celiac Disease

Teva Pharmaceutical Industries Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) and Biolojic Design Ltd announced that Teva initiated IND-enabling studies with BD9, a dual-specific multibody targeting both TSLP (Thymic stromal <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">lymphopoietin) and IL-13</a>.
Teva has an exclusive license to develop BD9 for TH2-driven inflammatory diseases such as <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45615937/teva-and-biolojic-design-initiate-ind-enabling-studies-of-bd9-a-multibody-designed-to-explore-the-" rel="noreferrer noopener">atopic dermatitis and asthma</a>.&nbsp;
By simultaneously blocking two key drivers of TH2-driven inflammation, BD9 can potentially improve outcomes for patients with conditions such as atopic dermatitis and asthma, where current treatments fall short.
Also Read: <a href="https://www.benzinga.com/general/biotech/25/05/45260240/teva-shares-climb-on-profit-beat-700-million-cost-plan-biopharma-pivot-momentum" target="_blank" rel="noreferrer noopener">Teva Shares Climb On Profit Beat, $700 Million Cost Plan, Biopharma Pivot Momentum</a>
The initiation of IND-enabling studies marks a critical milestone in translating this scientific innovation into a potential therapeutic option. It will pave the way for clinical trials and ultimately bring hope to underserved patient populations.
Under the terms of their agreement, Teva is developing BD9 worldwide.
In exchange, Biolojic is eligible to receive milestone payments based on the achievement of certain pre-clinical, clinical, regulatory, and commercial milestones, including the initiation of IND-enabling studies.
In May, the U.S. Food and Drug Administration (FDA) approved&nbsp;Teva and&nbsp;Alvotech's&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVO#NASDAQ">ALVO</a>) Selarsdi (ustekinumab-aekn) injection as interchangeable with the reference biologic&nbsp;Johnson &amp; Johnson's&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45199025/why-is-israel-based-generic-drug-focused-teva-pharmaceutical-stock-trading-higher-on-monday" rel="noreferrer noopener">Stelara (ustekinumab)</a>.
In January, The U.S. Food and Drug Administration (FDA) issued a warning regarding the risk of anaphylaxis, a rare but severe allergic reaction associated with glatiramer acetate, a medication used to treat relapsing <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/43174108/fda-warns-of-severe-allergic-reaction-risk-with-tevas-multiple-sclerosis-drug" rel="noreferrer noopener">forms of multiple sclerosis (MS)</a>.
Glatiramer acetate, sold under the brand name Copaxone by&nbsp;Teva and as generics like Glatopa, is an injectable medication designed to reduce the frequency of MS relapses.
In February, Axsome Therapeutics, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) signed a settlement agreement with&nbsp;Teva Pharmaceuticals.
The settlement resolves all patent litigation related to Axsome's Auvelity (dextromethorphan HBr –&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43601535/axsome-therapeutics-resolves-generic-patent-litigation-with-teva-over-depression-drug-analyst-maintains-axsome-as-top-pick-for-2025" rel="noreferrer noopener">bupropion HCl) product</a>.
Auvelity is approved in the U.S. for major depressive disorder.
The litigation resulted from Teva submitting an Abbreviated New Drug Application to the U.S. Food and Drug Administration (FDA) seeking approval to market a generic version of Auvelity in the U.S. before the expiration of applicable Axsome patents.
Price Action: TEVA stock is up 6.01% at $17.98 at the last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45624037/robert-f-kennedy-jr-says-cdc-drops-covid-vaccine-for-healthy-pregnant-women-kids">Robert F. Kennedy Jr. Says CDC Drops COVID Vaccine For &#8216;Healthy&#8217; Pregnant Women, Children</a></li>
</ul>
Photo via Shutterstock

Contracts

ALVO

Why Is Teva Stock Trading Higher On Tuesday?

WIIM

Teva Pharmaceutical Industries shares are trading higher after the company along with Biolojic Design initiated IND-enabling studies of BD9.

Teva And Biolojic Design Initiate IND-Enabling Studies Of BD9

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) ("Teva") announced today that it is increasing the maximum tender amount of its tender offer previously announced on May 19, 2025 from $2.0 billion (equivalent) aggregate cash purchase price (exclusive of accrued and unpaid interest) to approximately $2.25 billion (equivalent) aggregate cash purchase price (exclusive of accrued and unpaid interest) (the "Total Maximum Amount").
Teva is also increasing the Pool Tender Caps applicable to the Pool 2 Notes and the Pool 3 Notes (each, as defined below) from $250.0 million (equivalent) to $350.0 million (equivalent) and from $200.0 million (equivalent) to $350.0 million (equivalent), respectively, in each case representing aggregate cash purchase price (exclusive of accrued and unpaid interest).&nbsp;

Teva Pharma Upsizes Debt Tender Offer To $2.25B, Expands Pool 2 & Pool 3 Caps To $350M Each

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) ("Teva") announced today that it successfully&nbsp;upsized its offering and priced approximately $2,300,000,000 (equivalent) of its senior notes (the "Notes"). The principal amount of the offering was increased from the previously announced offering size of $2,000,000,000 (equivalent). Teva expects to use the net proceeds from the offerings (i) to fund the announced tender offers (collectively, the "Tender Offer") to purchase, for cash, its 3.150% Senior Notes due 2026, 4.750% Sustainability-Linked Senior Notes due 2027, 3.750% Sustainability-Linked Senior Notes due 2027, 7.875% Sustainability-Linked Senior Notes due 2029, 7.375% Sustainability-Linked Senior Notes due 2029 and 8.125% Sustainability-Linked Senior Notes due 2031&nbsp;(as it may be amended prior to expiration thereof), (ii) to pay fees and expenses in connection therewith and (iii) to the extent of any remaining proceeds, the repayment of outstanding debt upon maturity, tender offer or earlier redemption. Net proceeds may be temporarily invested pending application for their stated purpose.
The Notes consist of (i) Teva Pharmaceutical Finance Netherlands II B.V's ("Teva Finance II") €1,000,000,000 aggregate principal amount of 4.125% EUR-denominated Senior Notes maturing in 2031, (ii) Teva Pharmaceutical Finance Netherlands III B.V.'s ("Teva Finance III") $500,000,000 aggregate principal amount of 6.000% USD-denominated Senior Notes maturing in 2032 and (iii) Teva Pharmaceutical Finance Netherlands IV B.V.'s ("Teva Finance IV" and, together with Teva Finance II and Teva Finance III, the "Issuers") $700,000,000 aggregate principal amount of 5.750% USD-denominated Senior Notes maturing in 2030.
The settlement of the Notes is expected to occur on or about May 28, 2025, subject to customary closing conditions. The settlement of the Notes will satisfy the financing condition to the Tender Offer.

Offerings

Teva Pharmaceutical Industries Announces It Upsized Its Offering From $2B And Priced ~$2.3B Of Its Senior Notes

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) ("Teva") announced today that it has commenced tender offers (the "Offers") to purchase for cash for a combined aggregate purchase price (exclusive of accrued and unpaid interest) of up to $2,000,000,000 (equivalent) (the "Total Maximum Amount") of the following series of notes issued by finance subsidiaries of Teva and guaranteed by Teva:
<ul>
<li>USD 3.150% Senior Notes due 2026, CUSIP 88167AAE1 / ISIN US88167AAE10 (Registered), issued by Teva Pharmaceutical Finance Netherlands III B.V. (the "Pool 1 Notes");</li>
<li>USD 4.750% Sustainability-Linked Senior Notes due 2027, CUSIP 88167AAP6 / ISIN US88167AAP66 (Registered), issued by Teva Pharmaceutical Finance Netherlands III B.V. (the "Priority 2 Notes");</li>
<li>EUR 3.750% Sustainability-Linked Senior Notes due 2027, Common Code 240660709 / ISIN XS2406607098 (Registered), issued by Teva Pharmaceutical Finance Netherlands II B.V. (the "Priority 3 Notes" and together with the Priority 2 Notes, the "Pool 2 Notes");</li>
<li>USD 7.875% Sustainability-Linked Senior Notes due 2029, CUSIP 88167AAS0 / ISIN US88167AAS06 (Registered), issued by Teva Pharmaceutical Finance Netherlands III B.V. (the "Priority 4 Notes");</li>
<li>EUR 7.375% Sustainability-Linked Senior Notes due 2029, Common Code 259280443 / ISIN XS2592804434 (Registered), issued by Teva Pharmaceutical Finance Netherlands II B.V. (the "Priority 5 Notes"); and</li>
<li>USD 8.125% Sustainability-Linked Senior Notes due 2031, CUSIP 88167AAR2 / ISIN US88167AAR23 (Registered), issued by Teva Pharmaceutical Finance Netherlands III B.V. (the "Priority 6 Notes," and together with the Priority 4 Notes and the Priority 5 Notes, the "Pool 3 Notes," and the Pool 3 Notes, together with the Pool 1 Notes and the Pool 2 Notes, the "Notes").</li>
</ul>

Buybacks

Teva Launches $2 Billion Bond Buyback to Cut Debt Across Multiple Note Series

Teva Pharmaceuticals (NYSE and TASE: TEVA)&nbsp;today announced that Moody's Investor Services ("Moody's") has raised the company's corporate credit rating to Ba1, outlook stable; from Ba2, outlook positive.

Teva Pharmaceuticals Announced That Moody's Investor Services Has Raised The Company's Corporate Credit Rating To Ba1, Outlook Stable From Ba2, Outlook Positive

Teva Pharmaceuticals shares are trading higher after JP Morgan upgraded the stock from Neutral to Overweight and raised its price target from $21 to $23.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Guggenheim cut Intellia Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>) price target from $55 to $45. Guggenheim analyst Debjit Chattopadhyay maintained a Buy rating. Intellia Therapeutics shares closed at $8.12 on Friday. <a href="https://www.benzinga.com/quote/NTLA/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Canaccord Genuity raised the price target for Nexxen International Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEXN#NASDAQ">NEXN</a>) from $12 to $14. Canaccord Genuity analyst Maria Ripps maintained a Buy rating. Nexxen International shares closed at $11.54 on Friday. <a href="https://www.benzinga.com/quote/NEXN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Goldman Sachs slashed Warner Music Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WMG#NASDAQ">WMG</a>) price target from $35 to $28. Goldman Sachs analyst Stephen Laszczyk downgraded the stock from Buy to Neutral. Warner Music shares closed at $27.36 on Friday. See how other analysts <a href="https://www.benzinga.com/quote/WMG/analyst-ratings">view this stock</a>.</li>
<li>HC Wainwright &amp; Co slashed the price target for Ocugen, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCGN#NASDAQ">OCGN</a>) from $8 to $7. HC Wainwright &amp; Co. analyst Swayampakula Ramakanth maintained a Buy rating. Ocugen shares closed at $0.67 on Friday. <a href="https://www.benzinga.com/quote/OCGN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Needham slashed the price target for Vir Biotechnology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIR#NASDAQ">VIR</a>) from $19 to $14. Needham analyst Joseph Stringer maintained a Buy rating. Vir Biotechnology shares closed at $5.09 on Friday. <a href="https://www.benzinga.com/quote/VIR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JP Morgan raised Teva Pharmaceutical Industries Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NASDAQ">TEVA</a>) price target from $21 to $23. JP Morgan analyst Chris Schott upgraded the stock from Neutral to Overweight. Teva Pharmaceutical shares settled at $16.93 on Friday. <a href="https://www.benzinga.com/quote/TEVA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies increased Marriott International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>) price target from $226 to $303. Jefferies analyst David Katz upgraded the stock from Hold to Buy. Marriott shares closed at $257.97 on Friday. <a href="https://www.benzinga.com/quote/MAR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Barrington Research raised DENTSPLY SIRONA Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) price target from $20 to $21. Barrington Research analyst Michael Petusky maintained an Outperform rating. Dentsply Sirona shares closed at $15.81 on Friday.  <a href="https://www.benzinga.com/quote/XRAY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Rosenblatt slashed the price target for TeraWulf Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WULF#NASDAQ">WULF</a>) from $4.5 to $4. Rosenblatt analyst Chris Brendler maintained a Buy rating. TeraWulf shares settled at $3.01 on Friday. <a href="https://www.benzinga.com/quote/WULF/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>D. Boral Capital raised Medicus Pharma Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDCX#NASDAQ">MDCX</a>) price target from $14 to $27. D. Boral Capital analyst Jason Kolbert maintained a Buy rating. Medicus Pharma shares closed at $4.69 on Friday. <a href="https://www.benzinga.com/quote/MDCX/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying MAR stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="612" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12094338/image-127-1024x612.png" alt="" class="wp-image-911954" style="width:591px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12094338/image-127-1024x612.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12094338/image-127-300x179.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12094338/image-127-768x459.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12094338/image-127.png 1130w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45342900/5-stock-picks-last-week-from-wall-streets-most-accurate-analysts-5">5 Stock Picks Last Week From Wall Street&#8217;s Most Accurate Analysts</a> </li>
</ul>
Photo via Shutterstock

MDCX

NEXN

NTLA

OCGN

WULF

XRAY

Marriott International To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Keybanc analyst Steve Barger upgraded Federal Signal Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSS#NYSE">FSS</a>) from Sector Weight to Overweight and announced a $110 price target. Federal Signal shares closed at $89.56 on Friday. <a href="https://www.benzinga.com/quote/fss/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Argus Research analyst John Staszak upgraded the rating for Wayfair Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/W#NYSE">W</a>) from Hold to Buy and announced a $40 price target. Wayfair shares closed at $32.79 on Friday. <a href="https://www.benzinga.com/quote/W/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>DA Davidson analyst Peter Heckmann upgraded ACI Worldwide, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACIW#NASDAQ">ACIW</a>) from Neutral to Buy and maintained the price target of $60. ACI Worldwide shares closed at $46.56 on Friday. <a href="https://www.benzinga.com/quote/ACIW/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst David Katz upgraded the rating for Marriott International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>) from Hold to Buy and raised the price target from $226 to $303. Marriott International shares closed at $257.97 on Friday. <a href="https://www.benzinga.com/quote/MAR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Chris Schott upgraded Teva Pharmaceutical Industries Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) from Neutral to Overweight and raised the price target from $21 to $23. Teva Pharmaceutical shares closed at $16.93 on Friday. <a href="https://www.benzinga.com/quote/TEVA/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying W stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="584" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12090618/image-124-1024x584.png" alt="" class="wp-image-911884" style="width:583px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12090618/image-124-1024x584.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12090618/image-124-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12090618/image-124-768x438.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12090618/image-124.png 1102w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45342900/5-stock-picks-last-week-from-wall-streets-most-accurate-analysts-5">5 Stock Picks Last Week From Wall Street&#8217;s Most Accurate Analysts</a> </li>
</ul>
Photo via Shutterstock

Upgrades

Pre-Market Outlook

ACIW

This Wayfair Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday

Bonds

Press Releases

Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing Debt

Financing

Teva Announces Increase of the Maximum Tender Amount of its Debt Tender Offer and Increases to Pool Tender Caps for Pool 2 Notes and Pool 3 Notes

Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatment of Atopic Dermatitis and Asthma

Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference in June

Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA

Teva Reaffirms "Pivot to Growth" Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day

Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-'749 (olanzapine) to Date

New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025

IPOs

Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total Maximum Amount and Election of Early Settlement

Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

BGM Group

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co

Verona Pharma plc - American Depositary Shares

Verona Pharma

Viatris

Zoetis

Goldman Sachs

Truist Securities

JP Morgan

B of A Securities

Teva Pharm

Screenshot 2025-02-27 at 6.38.52 PM

Movers & Shakers

KMDA

How Kamada (NASDAQ: KMDA) Is Transforming Its Strategic Focus Into Commercial Growth

최근 13F 공시에 따르면 억만장자 투자자 스탠리 드러켄밀러의 가족 투자사인 듀케인(Duquesne)은 브로드컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) 주식을 전량 매각하는 동시에 주요 기술 기업에 대한 투자를 늘렸다.
무슨 일 있었나: 최근 미 증권거래위원회(SEC)에 제출된 자료에 따르면, 노련한 투자자인 드러켄밀러는 4분기에 브로드컴의 주식을 모두 매각했다. 이러한 움직임은 몇 달 전 칩 제조업체인 엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)에서 완전히 손을 뗀 이후에 나온 것이다.
드러켄밀러는 2024년 마지막 달에 기술 주식 포트폴리오를 크게 줄이면서 마이크로소프트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), 어도비(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>), 오토데스크(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>)의 모든 지분을 매각했다. 또한 스타벅스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>)와 보험사 처브(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CB#NYSE">CB</a>)의 주식도 완전히 매각했다.
이러한 매각에도 불구하고 드러켄밀러는 같은 분기에 여러 대형 기술 기업에 대한 투자를 늘려 알파벳(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>), 아마존(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) 그리고 일론 머스크의 전기차 제조사인 테슬라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)에 새로운 포지션을 취했다.
또한 유나이티트항공(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NYSE">UAL</a>), 델타항공(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>), 워너 브라더스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NYSE">WBD</a>), 스케처스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKX#NYSE">SKX</a>), 일라이 릴리(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)에 대한 새로운 투자를 시작했다.
듀케인에서 가장 중요한 지분을 보유하고 있는 종목은 임상 유전자 검사 회사인 나테라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>)로 2022년부터 보유하고 있다. 나테라 보유 지분이 전체 포트폴리오의 15%를 조금 넘는다. 한편, 듀케인은 테바 파마슈티컬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) 지분도 거의 6.3배나 늘렸다.
왜 중요한가: 조지 소로스의 헤지펀드를 관리했던 드러켄밀러는 현재 37억 2천만 달러에 달하는 투자금을 보유한 가족 투자사 듀케인을 통해 자신의 재산을 관리하고 있다.
억만장자 투자자 드러켄밀러 최근 움직임은 앞서 AI 주식을 매각한 이후에 나타난 것이다. 그는 2024년 3분기에 <a href="//www.benzinga.com/markets/equities/24/12/42668157/stanley-druckenmiller-dumps-streets-hottest-ai-stocks-heres-what-the-billionaire-investor-is-betting-on-next"" target="_blank" rel="noopener">엔비디아 주식을 모두 매각하고 팔란티어 보유 지분을 95%까지 크게 줄였다.</a> 이는 그해 엔비디아의 주식이 190% 가까이 상승하고 팔란티어의 주식이 386% 이상 상승하는 등 엔비디아와 팔란티어의 주식이 큰 폭으로 상승했음에도 불구하고 발생한 일이다.
지난 1년 동안 주가가 100% 이상 급등했음에도 불구하고 이번 분기에 브로드컴에서 철수한 것은 차익을 실현하기 위한 것으로 보인다. 한편, 다른 대형 기술주 추가는 기술 분야에 대한 그의 자신감이 커지고 있음을 보여 준다.
드러켄밀러는 작년에 83% 이상 급등한 테슬라를 포트폴리오에 추가했다. 그러나 지난달에는 글로벌 판매 감소, 중국의 규제 장애물, 실적 부진, 머스크의 정치 참여 증가로 인해 주가가 16% 이상 급락했다.
이미지: Shutterstock 
면책 조항: 이 콘텐츠는 부분적으로 AI 도구의 도움을 받아 작성되었으며, Benzinga 편집자가 검토하고 게시했습니다.
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

이들 10개 대형주는 지난 주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 위라이드(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WRD#NASDAQ">WRD</a>)의 주식이 97.62% 급등했다. 이는 엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)가 13F 제출을 통해 174만 주의 지분을 보유하고 있다고 공개한 후 발생한 일이다.
2. GDS 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDS#NASDAQ">GDS</a>)의 주식이 43.45% 상승했다. 이는 트럼프 대통령이 중국에서 오는 $800 이하의 소포에 대한 관세를 연기했다고 보도된 후 발생한 일이다. 또한, 중국의 딥시크(DeepSeek) AI 모델에 대한 낙관론도 최근 주가를 끌어올렸다.
3. 스프링웍스 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWTX#NASDAQ">SWTX</a>)의 주식이 42.58% 상승했다. 이는 머크 그룹(OTC:<a class="ticker" href="https://www.benzinga.com/stock/MKGAF#OTC">MKGAF</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MKKGY#OTC">MKKGY</a>)가 회사를 인수하기 위한 고급 논의를 진행 중이라고 발표한 후 발생한 일이다.
4. 리커젼 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>)의 주식이 40.59% 증가했다.
5. 세이블 오프쇼어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOC#NYSE">SOC</a>)의 주식이 39.09% 상승했다.
6. 진DX 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>)의 주식이 28.23% 상승했다. 이는 회사가 울트라래피드 전장유전체 시퀀싱(UltraRapid Whole Genome Sequencing)을 발표하여 48시간 내에 실행 가능한 결과를 제공한다고 발표한 후 발생한 일이다.
7. 브이넷 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNET#NASDAQ">VNET</a>)의 주식이 28.22% 상승했다. 이는 지난 주 중국의 딥시크 AI 모델과 관련된 AI 경쟁 우려로 하락한 후 반등 가능성이 제기된 것으로 보인다.
8. 인스페리티(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSP#NYSE">NSP</a>)의 주식이 25.99% 증가했다. 이는 회사가 예상보다 좋은 4분기 결과를 발표한 후 발생한 일이다.
9. 크리스퍼 테라퓨틱스 AG(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>)의 주식이 25.21% 상승했다. 이는 회사가 예상보다 좋은 4분기 재무 결과를 발표한 후 여러 애널리스트들이 주가 전망을 상향 조정한 후 발생한 일이다.
10. 액섬 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>)의 주식이 24.01% 상승했다. 이는 회사가 테바 파마슈티컬(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>)과의 모든 특허 소송을 해결하기 위한 합의에 도달한 후 발생한 일이다. 여러 애널리스트들이 주가 전망을 상향 조정했다.
다음 읽기:
<a href="https://kr.benzinga.com/news/usa/stocks/%EC%8A%88%ED%8D%BC-%EB%A7%88%EC%9D%B4%ED%81%AC%EB%A1%9C-%EC%9D%B8%ED%85%94-%EC%95%8C%EB%A6%AC%EB%B0%94%EB%B0%94-%EB%B0%8F-cvs-%EB%93%B1-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%83%81%EC%8A%B9%ED%95%9C-12/" target="_blank" rel="noopener">슈퍼 마이크로, 인텔, 알리바바 및 CVS 등 지난주 상승한 12개 대형주 (2월 10일-2월 14일)</a>
<a href="https://kr.benzinga.com/news/usa/stocks/%EB%A0%88%EB%94%A7-%EA%B3%A0%EB%8C%80%EB%94%94-%EB%B0%8F-%ED%8A%B8%EB%A0%88%EC%9D%B4%EB%93%9C-%EB%8D%B0%EC%8A%A4%ED%81%AC%EB%8A%94-%EB%93%B1-%EC%A7%80%EB%82%9C%EC%A3%BC-%ED%95%98%EB%9D%BD%ED%95%9C-11/" target="_blank" rel="noopener">레딧, 고대디 및 트레이드 데스크는 등 지난주 하락한 11개의 대형주 (2월 10일~2월 14일)</a>
사진 출처: WeRide
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

이들 12개 대형주들은 지난 주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 맨해튼 어소시에이츠(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MANH#NASDAQ">MANH</a>)의 주식은 회사가 2025 회계연도에 대한 부진한 가이던스를 발표한 후 27.92% 급락했다. <a href="https://www.benzinga.com//node/43315362" target="_blank" rel="noreferrer noopener">애널리스트들이 가격 예측을 하향 조정한 것</a>도 영향을 미쳤다.
2. 버티브 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>)의 주식은 20.02% 하락했다. 멜리우스 리서치(Melius Research)의 애널리스트 스콧 데이비스(Scott Davis)가 회사의 투자를 매수에서 보유로 하향 조정하고 <a href="https://www.benzinga.com/quote/vrt/analyst-ratings" target="_blank" rel="noreferrer noopener">125달러의 목표 주가를 발표</a>했다.
3. 컴포트 시스템즈 USA(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIX#NYSE">FIX</a>)의 주식은 딥시크(DeepSeek) <a href="https://www.benzinga.com//node/43254923" target="_blank" rel="noreferrer noopener">중국의 오픈 소스 AI 모델</a> 출시 이후 19.74% 하락했다.
4. 데커스 아웃도어 코퍼레이션(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>)의 주식은 회사가 <a href="https://www.benzinga.com//node/43356259" target="_blank" rel="noreferrer noopener">3분기 재무 결과를 발표</a>하자 18.33% 하락했다. 여러 애널리스트들이 <a href="https://www.benzinga.com/quote/deck/analyst-ratings" target="_blank" rel="noreferrer noopener">가격 예측을 하향 조정</a>했다.
5. 테바 파마슈티컬 인더스트리즈(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>)의 주식은 18.22% 하락했다. 회사가 <a href="https://www.benzinga.com//node/43303023" target="_blank" rel="noreferrer noopener">4분기 재무 결과를 발표</a>하자 애널리스트들이 <a href="https://www.benzinga.com/quote/teva/analyst-ratings" target="_blank" rel="noreferrer noopener">가격 예측을 하향 조정</a>했다.
6. 엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)의 주식은 <a href="https://www.benzinga.com//node/43220297" target="_blank" rel="noreferrer noopener">중국의 딥시크로 인한 GPU 지출 열풍에 대한 의구심</a>으로 인해 지난 주에 15.81% 하락했다. 또한 트럼프 정부 관계자들이 중국 판매를 추가로 제한하는 방안을 논의했다는 보도도 주가에 영향을 미쳤다.
7. 엠코 그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EME#NYSE">EME</a>)의 주식은 15.72% 하락했다.
8. 벤처 글로벌(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VG#NYSE">VG</a>)의 주식은 14.79% 하락했다.
9. 슈퍼 마이크로 컴퓨터(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>)의 주식은 <a href="https://www.benzinga.com//node/43231443" target="_blank" rel="noreferrer noopener">중국의 딥시크로 인한</a> 투자자들의 우려로 인해 지난 주에 14.28% 하락했다.
10. 유나이티드 파슬 서비스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>)의 주식은 혼재된 4분기 실적 발표 이후 애널리스트들이 <a href="https://www.benzinga.com//node/43389661" target="_blank" rel="noreferrer noopener">목표 주가를 하향 조정</a>하자 14.13% 급락했다.
11. 콴타 서비스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PWR#NYSE">PWR</a>)의 주식은 14.08% 하락했다. 씨티그룹의 애널리스트 앤드루 카플로위츠(Andrew Kaplowitz)는 매수 등급을 유지하고 <a href="https://www.benzinga.com/quote/pwr/analyst-ratings" target="_blank" rel="noreferrer noopener">가격 예측을 394달러에서 371달러로 하향 조정</a>했다.
12. 콘스텔레이션 에너지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>)의 주식은 중국의 딥시크 AI 모델로 인한 AI 경쟁 우려로 13.66% 하락했다. 이는 <a href="https://www.benzinga.com//node/43254923" target="_blank" rel="noreferrer noopener">AI 관련 부문에 부정적인 영향</a>을 미쳤다.
다음 읽어보기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EC%95%8C%EB%A6%AC%EB%B0%94%EB%B0%94-ibm-%EB%B0%8F-%EB%93%80%EC%98%A4%EB%A7%81%EA%B3%A0-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EA%B3%A0-%EC%84%B1%EA%B3%BC%EB%A5%BC-%EB%B3%B4%EC%97%AC%EC%A4%80-10/" target="_blank" rel="noopener">알리바바, IBM 및 듀오링고 지난주 최고 성과를 보여준 10개 대형주 중 일부 (1월 27일-1월 31일)</a></li>
</ul>
사진 출처: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

월가가 <a href="https://www.benzinga.com/news/treasuries/24/12/42674886/santa-rally-kicks-off-on-wall-street-stocks-gain-tesla-soars-bitcoin-hits-98000">산타 랠리 시즌의 긍정적인 시작</a>을 맞이하며, 크리스마스 휴일을 앞둔 단축 세션에서 모든 주요 지수와 섹터가 상승 마감했다. S&amp;P 500이 1.1% 상승하며 세 번째 연속 상승세를 기록한 반면, 기술주 중심의 나스닥 100은 1.35% 상승해 지난주의 손실을 거의 만회했다. 다우 존스 산업평균지수는 0.9% 상승으로 세션을 마쳤다.
여기서 주목을 받은 상위 주식들은 다음과 같다.
테슬라 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)
테슬라의 주식은 7.35% 상승하여 $462.25로 마감했다. 주가는 장중 최고 $462.78, 최저 $435.14를 기록했다. 주식의 52주 최고가는 $488.54, 최저가는 $138.80이다. CEO 일론 머스크는 테슬라가 <a href="https://www.benzinga.com/24/12/42667044/teslas-valuation-could-exceed-all-transport-companies-but-spacex-ceo-elon-musk">모든 운송 회사의 가치를 초과할 수 있다</a>고 언급했다. 이는 많은 일과 좋은 아이디어가 필요하다고 덧붙였다.
아빙거 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGR#NASDAQ">AVGR</a>)
아빙거의 주식은 125.72% 상승하여 $1.45에 거래되었으며, 장중 최고 $1.93, 최저 $1.01를 기록했다. 이 주식의 52주 최고가는 $5.45, 최저가는 $0.39이다. 이 회사는 지난주 &#8220;말단이 분리 가능한 카테터 장치(말초동맥질환 치료용)&#8221;이라는 제목의 미국 특허 <a href="https://www.benzinga.com/24/12/42666807/why-carbon-revolution-shares-are-trading-higher-by-around-62-here-are-20-stocks-moving-premarket" target="_blank" rel="noopener" data-google-interstitial="false">허용 통지를 받았다</a>고 발표했다.
젯.AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JTAI#NASDAQ">JTAI</a>)
젯.AI의 주식은 79.24% 상승하여 $6.13에 거래되었다. 장중 최고가는 $9.99, 최저가는 $5.85였다. 이 주식의 52주 최고가는 $607.51, 최저가는 $3.29이다. 이 회사는 <a href="https://www.benzinga.com/news/small-cap/24/12/42674451/why-is-jet-ai-stock-trading-over-100-on-tuesday" target="_blank" rel="noopener" data-google-interstitial="false">개인 제트기 예약을 간소화</a>하기 위해 설계된 고급 인공지능(AI) 모델 &#8220;아바(Ava)&#8221;를 출시했으며, 이는 주가에 큰 상승 효과를 주었다.
테바 파마수티컬스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>)
테바의 주식은 0.95% 상승하여 $22.42로 마감했다. 장중 최고가는 $22.50, 최저가는 $22.19였다. 이 주식의 52주 최고가는 $22.50, 최저가는 $10.34이다. 스탠리 드러켄밀러(Stanley Druckenmiller)의 듀케인 패밀리 오피스(Duquesne Family Office)가 3분기에 140만 주 이상의 주식을 매입하여 <a href="https://www.benzinga.com/24/12/42668157/stanley-druckenmiller-offloads-streets-hottest-ai-stocks-heres-what-the-billionaire-investor-is-loading-up-on" target="_blank" rel="noopener" data-google-interstitial="false">테바 파마수티컬스의 지분</a>을 늘렸다.
넷플릭스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>)
넷플릭스의 주식은 2.27% 상승하여 $932.12로 마감했다. 장중 최고가는 $935.85, 최저는 $911.70이었다. 이 주식의 52주 최고가는 $941.75, 최저가는 $461.86이다. 넷플릭스는 최근 <a href="https://kr.benzinga.com/news/usa/stocks/2025%EB%85%84-%EC%9E%AC%ED%8C%90%EC%9D%84-%EC%95%9E%EB%91%90%EA%B3%A0-%EB%B8%8C%EB%A1%9C%EB%93%9C%EC%BB%B4%EA%B3%BC-%EB%84%B7%ED%94%8C%EB%A6%AD%EA%B0%80-%ED%8A%B9%ED%97%88-%EB%B6%84%EC%9F%81%EC%9C%BC/" target="_blank" rel="noopener">브로드컴의</a> 자회사 VM웨어를 상대로 특허 침해 소송을 제기했다. 이는 향후 운영에 영향을 미칠 수 있다.
벤징가의 주요 프리마켓 이동주 및 뉴스와 함께 거래를 준비하세요.
다음 읽기:
<ul>
<li><a href="https://www.benzinga.com/24/12/42639340/bernie-sanders-is-all-for-canada-becoming-the-51st-state-if-the-u-s-will-also-adopt-universal-healthcare?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">버니 샌더스는 캐나다가 51번째 주가 되는 것에 &#8216;찬성&#8217;한다. 단, 미국도 보편적 의료 보험을 도입해야 한다</a></li>
</ul>
이 기사는 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>를 사용하여 생성되었으며, <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>에 의해 편집되었습니다.
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

AVGR

JTAI

NFLX

화요일 주목받은 주식: 테슬라, 아빙거, 젯.AI, 테바 그리고 넷플릭스

JP모건에 따르면 미국 대형 바이오제약주는 2년 연속 전체 시장 대비 저조한 실적을 기록했으며, 2025년에 대한 투자자들의 전망은 혼조세를 보이고 있다.
강력한 펀더멘털과 신약 파이프라인의 발전에도 불구하고 정치적 불확실성과 섹터 순환과 같은 요인으로 인해 S&amp;P 500 대비 바이오제약 섹터의 성과가 저조했다.
2024년 바이오제약 주식은 9.6% 상승하여 S&amp;P 500의 28.5% 상승률에 미치지 못했다. 그러나 JP모건 애널리스트들은 몇몇 주요 기업에 대해 긍정적인 전망을 유지하고 있다.
JP모건에서 가장 많이 추천하는 일라이 릴리(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)는 당뇨병 및 비만 치료제인 <a href="https://www.benzinga.com/general/biotech/24/10/41622207/eli-lilly-q3-earnings-mounjaro-sales-more-than-double-takes-2-98-billion-hit-to-profit-cuts-annua">마운자로(Mounjaro)와 젭바운드(Zepbound)</a>에서 지속적인 성장을 보일 것으로 예상된다. 또한 JP모건은 일라이 릴리의 강력한 파이프라인을 강조하면서 2030년대까지 두 자릿수 매출과 수익 성장을 예측했다.
브리스톨-마이어스 스퀴브(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)는 최고 매출 100억 달러를 달성할 수 있는 조현병 치료제인 코벤피(Cobenfy)의 강력한 잠재력으로 JP모건의 &#8216;포커스 리스트&#8217;에 추가되었다.
마찬가지로 머크(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)와 리제네론 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>)는 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40168774/mercks-blockbuster-vaccine-gardasil-sales-in-china-analyst-highlights-challenges-an">주요 제품에 영향을 미치는</a> <a href="https://www.benzinga.com/general/biotech/24/04/38208816/eye-drug-eylea-price-manipulation-regeneron-faces-us-justice-department-allegations-over-medicare">경쟁 압력</a> 및 지역 역학과 관련된 2024년의 어려움에 이어 2025년에는 회복될 것이르오 예상된다.
길리어드 사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>)는 <a href="https://www.benzinga.com/quote/GILD">HIV 예방을 위한</a> 레나카파비르(lenacapavir)의 2025년 중반 출시가 예상됨에 따라 성장할 것으로 예상된다.
또한 애브비(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)는 단기적인 <a href="https://www.benzinga.com/quote/ABBV">파이프라인 개발</a>이 적음에도 불구하고 스카이리지(Skyrizi)와 린보크(Rinvoq) 판매 호조에 힘입어 밸류에이션이 매력적이라고 보았다.
한편, 동물 건강 관련 주식도 2025년에 반등할 것으로 예상한다. JP 모건은 조에티스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>)를 이 분야에서 가장 강력한 선택지로 보고 있으며, 고배당 매출 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41722660/zoetis-q3-earnings-beat-companion-animal-segment-growth-gives-confidence-into-2025-" target="_blank" rel="noreferrer noopener">성장과 마진 확장</a>의 잠재력을 언급했다. 아이덱스 래버러토리스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>)는 또 다른 다른 확실한 선택이며, 성과는 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41659873/idexx-laboratories-adjusts-guidance-as-q3-revenue-growth-slows-analyst-notes-fewer-" target="_blank" rel="noreferrer noopener">수의사 방문 수 회복</a>에 달려 있다. 한편 엘랑코 애니멀 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELAN#NYSE">ELAN</a>)는 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41817807/elanco-animal-q3-earnings-profit-beat-new-products-and-stabilized-business-to-drive" target="_blank" rel="noreferrer noopener">신제품 출시</a>와 관련된 불확실성에 직면해 있다.
그리고 특수 의약품 부문은 2024년에 가격 안정성과 공급 역학 개선의 혜택을 받아 조기에 안정화 조짐을 보였다. 페리고(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRGO#NYSE">PRGO</a>)와 비아트리스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>)는 유망한 기회로 강조되었으며 테바 파마슈티컬(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>)는 올해 강력한 임상 시험 <a href="https://www.benzinga.com/general/biotech/24/12/42561832/teva-pharmaceutical-releases-impressive-phase-2-candidate-data-for-gastro-related-diseases" target="_blank" rel="noreferrer noopener">결과를 발표했지만</a> 성장 문제에 직면할 수 있다.
이 기사도 읽어보세요: <a href="https://kr.benzinga.com/news/usa/stocks/%ED%80%80%ED%85%80-%EC%BB%B4%ED%93%A8%ED%8C%85-%EB%B8%94%EB%9E%99%EB%B2%A0%EB%A6%AC-%EB%A3%A8%EC%8B%9C%EB%93%9C-%EB%93%B1-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EB%8C%80-%EC%83%81%EC%8A%B9%ED%95%9C/">퀀텀 컴퓨팅, 블랙베리, 루시드 등 지난주 최대 상승한 중형주 (12월 16일~20일)</a>
사진 출처: Shutterstock
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

ELAN

GILD

IDXX

PRGO

REGN

일라이 릴리, 머크 등 대형 바이오제약사 2025년 전망: JP모건

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 테바 파마수티컬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>)의 주식은 회사와 사노피 SA(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>)가 <a href="https://www.benzinga.com//node/42531132" target="_blank" rel="noreferrer noopener">궤양성 대장염 및 크론병</a>에 대한 두바키투그(Duvakitug)의 2b상 시험에서 1차 평가변수가 충족되었다고 발표한 후 주가는 33.88% 상승했다.
2. 클라비요(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVYO#NYSE">KVYO</a>)의 주식은 12.85% 급등했다.
3. 올리브 가든 모회사 다덴 레스토랑(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>)의 주식은 회사가 예상보다 좋은 2분기 EPS와 <a href="https://www.benzinga.com//node/42585797" target="_blank" rel="noreferrer noopener">2025 회계연도 매출 전망</a>을 발표한 후 12.54% 상승했다. 여러 애널리스트들이 <a href="https://www.benzinga.com/quote/dri/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 전망을 상향 조정</a>했다.
4. 닥시미티(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>)의 주식은 10.91% 상승했다. 스티븐스 앤 컴퍼니(Stephens &amp; Co.)가 중립 등급으로 커버리지를 시작하고 <a href="https://www.benzinga.com/quote/docs/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 전망을 $55</a>로 제시했다.
5. 버켄스탁 홀딩(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIRK#NYSE">BIRK</a>)의 주식은 회사가 예상보다 좋은 4분기 재무 결과와 2025 회계연도 가이던스를 발표한 후 9.70% 상승했다. 여러 애널리스트들이 <a href="https://www.benzinga.com//node/42599431" target="_blank" rel="noreferrer noopener">주가 전망을 상향 조정</a>했다.
6. 자빌(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBL#NYSE">JBL</a>)의 주식은 회사가 예상보다 좋은 <a href="https://www.benzinga.com//node/42553094" target="_blank" rel="noreferrer noopener">1분기 EPS와 매출</a>을 발표한 후 7.30% 상승했다. 여러 애널리스트들이 <a href="https://www.benzinga.com/quote/jbl/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 전망을 상향 조정</a>했다.
7. 뉴로크린 바이오사이언시스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>)의 주식은 6.88% 상승했다. FDA가 크레네시티(크리네서폰트, crinecerfont) 캡슐과 경구용 용액을 <a href="https://www.benzinga.com//node/42508449" target="_blank" rel="noreferrer noopener">부신피질호르몬 대체 요법 보조 치료제로 승인</a>했다. 이는 4세 이상의 성인 및 소아 환자의 선천성 부신 효소 결핍증(CAH) 치료에 사용된다.
8. 게임스탑(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>)의 주식은 지난 주 6.54% 상승했으며, 이는 3분기 실적의 강세가 지속된 결과이다.
9. 닥터 레디스 래버러토리스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDY#NYSE">RDY</a>)의 주식은 6.29% 상승했다.
10. 리 오토(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>)의 주식은 지난주 6.13% 상승했다.
 
사진 제공: Sundry Photography via Shutterstock


Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

BIRK

CHWY

DOCS

KVYO

NBIX

테바, 리 오토 및 다덴 레스토랑이 지난주 최고 성과를 보여준 10개 대형주 중 일부 (12월 16-20일)

화요일(17일) 미국 증시는 11월 소매판매 발표 이후 주요 지수가 하락했다. 소매판매 데이터는 연준의 내년 금리인하 지연 가능성에 대한 우려를 불러일으켰다.
S&amp;P 500 지수와 다우존스 산업평균지수는 각각 0.4%, 0.6% 하락했고, 나스닥 100 지수는 지정학적 긴장감으로 반도체주가 하락세를 주도하며 0.3% 하락했다.
화요일에 개인 투자자와 트레이더들의 주목을 받은 주식은 다음과 같다.
1. 뉴클러스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUKK#NASDAQ">NUKK</a>)
뉴클러스 주가는 754.68% 급등하여 11.88로 마감했다. 주가는 장중 최고가 17.66달러, 최저가 1.84달러를 기록했으며 52주 범위는 34.16~0.40달러다.
이러한 급격한 상승은 뉴클러스가 이스라엘의 아이언 돔 미사일 방어 시스템 공급업체인 리몬(RIMON)의 지분을 상당 부분 보유하고 있는 스타 26 캐피탈(Star 26 Capital Inc.)의 지분 51%를 인수한다는 발표에 따른 것이었다. 이번 인수를 통해 뉴클러스는 방위 산업에 대한 야망을 <a href="https://www.benzinga.com/24/12/42535878/why-nukkleus-stock-is-gaining-tuesday">더욱 강화할 것이다.</a>
2. 마이크론 테크놀로지 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>)
마이크론 테크놀로지는 0.31% 소폭 상승하여 108.60 달러로 마감했다. 주가는 최고가 110.49 달러에서 최저 107.68 달러 사이에서 변동했으며 52주 범위는 157.54~78.63달러다. 마이크론은 1분기 실적을 발표할 예정이며, 애널리스트들은 매출이 전년 대비 크게 증가한 87억 2천만 달러에 달할 것으로 <a href="https://www.benzinga.com/24/12/42541544/micron-q1-earnings-preview-analyst-estimates-why-company-is-well-positioned-heading-into-2025">예상하고 있다.</a> 마이크론은 최근 몇 분기 동안 지속적으로 예상치를 상회하는 실적을 달성했다.
3. 테바 파마슈티컬 인더스트리즈 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>)
테바 파마슈티컬은 주가가 26.47% 상승하여 20.88달러로 마감했다. 주가는 장중 최고가 21.05달러, 최저가 19.03달러를 기록했으며 52주 범위는 21.05~10달러다. 이러한 상승은 염증성 장 질환을 표적으로 하는 단일 클론 항체에 대한 2b상 연구가 성공적으로 완료되어 임상적 관해율에서 <a href="https://www.benzinga.com/24/12/42531132/why-are-teva-and-sanofi-stocks-trading-higher-on-tuesday" target="_blank" rel="noopener">긍정적인</a> 결과를 달성한 데 따른 것이었다.
4. 퀀텀 컴퓨팅 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>)
퀀텀 컴퓨팅 주가는 51.53% 상승하여 16.79달러로 마감했다. 주식의 장중 범위는 18.06~12.60달러였고, 52주 범위는 18.06~0.35달러였다. 이번 주가 급등은 퀀텀 컴퓨팅이 데이터 품질과 정확성을 향상시키기 위해 Dirac-3 머신을 활용하여 이미징 및 데이터 처리를 지원하는 NASA와의 <a href="https://www.benzinga.com/24/12/42533581/quantum-computing-stock-is-rising-tuesday-heres-why" target="_blank" rel="noopener">주요 계약</a>을 발표한 후 나타났다.
5. 테슬라 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)
테슬라는 3.64% 상승하여 479.86달러에 마감했다. 장중 최고가 483.99달러, 최저가 457.51달러였으며 52주 범위는 483.99~138.8달러였다. 애널리스트인 댄 아이브스는 테슬라가 도널드 트럼프 대통령 당선인의 행정부에서 인공지능과 규제 완화에 힘입어 예상되는 기술 부문 확장의 <a href="https://www.benzinga.com/markets/equities/24/12/42522531/tesla-will-be-the-biggest-winner-in-the-trump-era-says-dan-ives-predicts-nasdaq-at-25000-in-18-months-get-the-popcorn-out" target="_blank" rel="noopener">주요 수혜자</a>가 될 것이라고 예측했다.
이미지: Shutterstock.com
벤징가의 <a href="https://editorial.benzinga.com/wp-admin/Premarket%20Movers%20&amp;%20News" target="_blank" rel="noopener">프리마켓 동향 및 뉴스</a>로 하루의 거래를 준비하세요.
이 기사는 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>를 사용하여 생성되었으며 <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>이 편집했습니다.
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

NUKK

QUBT

화요일 주목받은 주식: 뉴클러스, 마이크론, 테바 파마슈티컬, 퀀텀 컴퓨팅 및 테슬라

이들 대형주들은 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
<ol>
<li>테바 파마슈티컬 인더스트리즈(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>)의 주가는 회사가 엇갈린 1분기 재무 결과를 발표하고 <a href="https://www.benzinga.com//node/38709408" target="_blank" rel="noreferrer noopener">위약과 비교하여 정신분열증</a>이 있는 성인 환자를 대상으로 한 TEV-&#8216;749의 3상 솔라리스(SOLARIS) 시험의 효능 부분 결과를 발표했한 후 16.24% 급등했다.</li>
<li>토스트(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOST#NYSE">TOST</a>)의 클래스 A 주식은 2024년 1분기 강력한 재무 결과로 14.71% 상승했다. 이 회사의 매출은 10억 7,500만 달러로 <a href="https://www.benzinga.com//node/38684417" target="_blank" rel="noreferrer noopener">추정치 10억 4,100만 달러</a>를 넘어섰다. 몇몇 분석가들은 <a href="https://www.benzinga.com//node/38710825" target="_blank" rel="noreferrer noopener">주식의 목표 가격</a>을 높였다.</li>
<li>앱러빈(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>)의 주가는 회사가 <a href="https://www.benzinga.com//node/38715910" target="_blank" rel="noreferrer noopener">예상보다 나은 1분기 재무 결과</a>를 보고한 후 13.28% 상승했다. 여러 분석가가 주식의 <a href="https://www.benzinga.com//node/38735571" target="_blank" rel="noreferrer noopener">목표 가격</a>을 높였다.</li>
<li>비스트라(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VST#NYSE">VST</a>)의 주가는 S&amp;P 500에 합류할 것이라고 발표한 후 13.25% 상승했으며 일부 분석가는 주식의 <a href="https://www.benzinga.com/quote/vst/analyst-ratings" target="_blank" rel="noreferrer noopener">목표 가격</a>을 높였다.</li>
<li>인터내셔널 플레이버 &amp; 프래그런스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IFF#NYSE">IFF</a>)의 주가는 회사가 강력한 1분기 실적을 보고하고 FY24 매출이 <a href="https://www.benzinga.com//node/38653308" target="_blank" rel="noreferrer noopener">가이던스 범위의 상한선</a>을 향할 것으로 예상한 후 11.22% 상승했다. 몇몇 분석가는 <a href="https://www.benzinga.com/quote/iff/analyst-ratings" target="_blank" rel="noreferrer noopener">주식의 목표 가격</a>을 높였다.</li>
<li>스테리스(아일랜드)(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>)의 주가는 회사가 예상보다 나은 4분기 재무 결과를 보고한 후 10.72% 상승했다. 이 회사는 유럽에서 <a href="https://www.benzinga.com//node/38714045" target="_blank" rel="noopener noreferrer">의료 수술 사업</a>의 구조 조정 계획을 발표했다.</li>
<li>콘스텔레이션 에너지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>)의 주가는 엇갈린 FY24 1분기 실적을 보고한 후 8.56% 상승했다. 일부 분석가는 주식 <a href="https://www.benzinga.com/quote/ceg/analyst-ratings" target="_blank" rel="noopener noreferrer">목표</a> 가격을 높였다.</li>
<li>에머슨 일렉트릭(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMR#NYSE">EMR</a>)의 주가는 예상보다 나은 <a href="https://www.benzinga.com//node/38702517" target="_blank" rel="noopener noreferrer">2분기 실적</a>을 보고하고 FY24 지침을 상향 조정한 후 7.99% 상승했다. 많은 분석가가 해당 주식의 <a href="https://www.benzinga.com//node/38728407" target="_blank" rel="noopener noreferrer">목표</a> 가격을 변경했다.</li>
<li>에퀴닉스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQIX#NASDAQ">EQIX</a>)의 주가는 엇갈린 2024년 <a href="https://www.benzinga.com//node/38736613" target="_blank" rel="noopener noreferrer">1분기 실적</a>을 발표한 후 6.9% 상승했다.</li>
<li>인터내셔널 페이퍼(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IP#NYSE">IP</a>)의 주가는 수자노(Suzano)가 <a href="https://www.benzinga.com//node/38681160" target="_blank" rel="noreferrer noopener">회사 인수</a>를 제안했다는 보도에 따라 5.68% 상승했다.</li>
</ol>
참조: <a href="https://www.benzinga.com/news/24/05/38779404/last-weeks-worst-performing-stocks-are-these-10-large-cap-stocks-in-your-portfolio-may-5-may-11-2024">지난주 최악의 수익을 올린 주식: 당신의 포트폴리오에 이 대형주들이 있나요? (5월 5일~11일)</a>
사진: 셔터스톡

Comments

Teva Pharmaceutical Indus

뉴스

에 대한 최신 뉴스 Teva Pharmaceutical Indus (NYSE:TEVA) 주식

화요일, 2월 18, 2025

일요일, 2월 16, 2025

일요일, 2월 02, 2025

수요일, 12월 25, 2024

월요일, 12월 23, 2024

일요일, 12월 22, 2024

수요일, 12월 18, 2024

일요일, 5월 12, 2024

수요일, 5월 08, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌